stockrow
Saturday 7 November 2026
Export EIKN’s income statement to Excel — free account
Eikon Therapeutics, Inc.
EIKN Healthcare Biotechnology
5.92
0.08
+1.37%
Follow EIKN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (244) | (324) | (345) | +33.0% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (244) | (324) | (601) | +33.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (96.76) | (115.29) | (67.94) | +19.1% | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (53.50) | (65.14) | (6.94) | +21.8% | ||||||
| Capex | — | — | — | — | — | — | — | — | (33.66) | (16.15) | (1.27) | (52.0%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (87.15) | (81.29) | (8.22) | (6.7%) | ||||||
| Book value | — | — | — | — | — | — | — | — | (226.98) | (303.75) | 8.62 | +33.8% | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 3 | 3 | 23 | +14.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (135) | (189) | (376) | +39.8% | |||||
| Capex | — | — | — | — | — | — | — | — | (85) | (47) | (69) | (44.9%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (220) | (235) | (445) | +7.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 171 | 294 | 492 | +71.4% | |||||
| Net debt | — | — | — | — | — | — | — | — | (221) | (336) | (532) | +52.5% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (572) | (879) | 467 | +53.7% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (61.45) | (90.08) | (61.4) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 45.99 | 0.00 | +46.0 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 384 | 384 | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 25 Oct 2026
Eikon Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AUTL Autolus Therapeutics PLC Sponsored ADR | $335.4M | — (loss-making) | — (loss-making) | +118.37% (above 0%: growing) | n/m | +67.55% (above 0%: growing) | 55.20% | (95.95%) | Compare |
| IRD Opus Genetics, Inc. | $333.2M | — (loss-making) | — (loss-making) | −73.80% (below 0%: shrinking) | n/m | −16.37% (below 0%: shrinking) | 100.00% | (2,182.78%) | Compare |
| FENC Adherex Technologies Inc. | $329.3M | — (loss-making) | 34.1× | +85.18% (above 0%: growing) | n/m | +101.36% (above 0%: growing) | 95.97% | 9.72% | Compare |
| PROK ProKidney Corp. | $322.0M | — (loss-making) | — (loss-making) | −32.13% (below 0%: shrinking) | n/m | −28.03% (below 0%: shrinking) | 100.00% | (32,248.67%) | Compare |
| EIKN Eikon Therapeutics, Inc. | $316.3M | — (loss-making) | — | — | n/m | +15.18% (above 0%: growing) | — | 0.00% | |
| ALEC Alector, Inc. | $309.9M | 6.6× | — (loss-making) | +4,895.89% (above 0%: growing) | n/m | +25.73% (above 0%: growing) | 100.00% | 76.04% | Compare |
| XFOR X4 Pharmaceuticals, Inc. | $304.4M | — (loss-making) | — (loss-making) | +63.12% (above 0%: growing) | n/m | +27.45% (above 0%: growing) | 82.18% | (694.37%) | Compare |
| BNTC Benitec Biopharma Limited | $301.5M | — (loss-making) | — (loss-making) | −85.42% (below 0%: shrinking) | n/m | +38.90% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GALT Galectin Therapeutics Inc. | $301.0M | — (loss-making) | — | — | n/m | +63.06% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $315.9M | — | — | +63.12% | — | +33.18% | 89.07% | (47.97%) |
Eikon Therapeutics, Inc. (EIKN) Latest News
No news at this impact. Lower the threshold for more.